Dyne
dyne.org
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Empowering artists, creatives and citizens for more than 20 years.
News
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action da...
Read more
Report
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering function...
Read more
Report
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
Read more
Report
Do Not Turn Child Protection Into Internet Access Control
Age verification turns the open internet into a permission system and pushes control away from families, schools, and users.
Read more
Report
The Future Was Federated
A dissertation on a journey through the evolution of decentralized social media and the necessity for active, conscious digital citizenship, with all the power and danger that entails.
Read more
Report
Pro access
Upgrade to see all 36 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.